Drug search by name

Nivolumab Intravenous and Thalomid

Determining the interaction of Nivolumab Intravenous and Thalomid and the possibility of their joint administration.

Check result:

Nivolumab Intravenous <> Thalomid

Relevance: 01.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using medications like nivolumab together with thalidomide and dexamethasone for the treatment of multiple myeloma may increase the risk of serious and life-threatening side effects as well as death compared to thalidomide and dexamethasone alone. This finding is based on results from two investigational studies. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established. In two randomized clinical trials of patients with multiple myeloma, the addition of pembrolizumab to a regimen of thalidomide analog plus dexamethasone resulted in increased mortality and toxicity. In the first trial (n=249), investigators reported a greater than 50% increase in relative risk of death in patients with relapsed and refractory multiple myeloma receiving pomalidomide and low-dose dexamethasone with pembrolizumab compared to controls receiving the treatment without pembrolizumab. There was also an 18% increase of severe, grade 3 to 5 toxicity and 17% increase of serious adverse events relative to the control arm. In the second trial (n=301), the relative risk of death was more than doubled in newly diagnosed patients with multiple myeloma receiving lenalidomide and low-dose dexamethasone with pembrolizumab compared to controls. The incidence of severe, grade 3 to 5 toxicity was increased by 22% and serious adverse events increased by 15% relative to controls.

MANAGEMENT: Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.

References

U.S. Food & Drug Administration (FDA) "FDA alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating KEYTRUDA (pembrolizumab) in patients with multiple myeloma. Available from: URL: https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm?source" ([2017, Sep 20]):
"Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc, Vancouver, AZ.
"Product Information. Revlimid (lenalidomide)." Celgene Corporation, Summit, NJ.
"Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.
"Product Information. Keytruda (pembrolizumab)." Merck & Company Inc, Whitehouse Station, NJ.

Nivolumab Intravenous

Generic Name: nivolumab

Brand name: Opdivo

Synonyms: Nivolumab

What is Nivolumab Intravenous?

Thalomid

Generic Name: thalidomide

Brand name: Thalomid

Synonyms: n.a.

What is Thalomid?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions